TYRA Stock Price, Tyra Biosciences, Inc. Quote, Chart

Market Summary

USD18.31-0.79

Delayedas of 17 May 2024, 12:57 pm

-4.14%

TYRA Stock Price

View Fullscreen

TYRA RSI Chart

TYRA Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-13.3

Price/Free Cashflow

-15.88

TYRA Price/Earnings (Trailing)

TYRA Profitability

Return on Equity

-19.35%

Return on Assets

-18.64%

Free Cashflow Yield

-6.3%

TYRA Fundamentals

TYRA Earnings

Earnings (TTM)

-75.4M

Earnings Growth (Yr)

-53.13%

Earnings Growth (Qtr)

20.32%

Breaking Down TYRA Revenue

52 Week Range

12.3119.74

(Low)(High)

Last 7 days

7.8%

Last 30 days

30.6%

Last 90 days

-1.3%

Trailing 12 Months

51.3%

How does TYRA drawdown profile look like?

TYRA Financial Health

Current Ratio

44.83

TYRA Investor Care

Shares Dilution (1Y)

23.44%

Diluted EPS (TTM)

-1.69

Tracking the Latest Insider Buys and Sells of Tyra Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	tada hiroomi	acquired	12,947	6.579	1,968	chief medical officer
Mar 15, 2024	harris todd	acquired	12,368	6.579	1,880	president and ceo
Mar 15, 2024	fuhrman alan	acquired	11,629	12.478	932	chief financial officer
Mar 11, 2024	bensen daniel	sold	-4,000	20.00	-200	chief operating officer
Mar 07, 2024	bensen daniel	sold	-1,360	20.00	-68.00	chief operating officer
Mar 06, 2024	bensen daniel	sold	-34,819	20.092	-1,733	chief operating officer
Mar 05, 2024	bensen daniel	sold	-23,802	20.0189	-1,189	chief operating officer
Mar 04, 2024	bensen daniel	sold	-101,654	20.0778	-5,063	chief operating officer
Mar 01, 2024	bensen daniel	sold	-58,111	20.0386	-2,900	chief operating officer
Feb 29, 2024	bensen daniel	sold	-41,003	20.0016	-2,050	chief operating officer

Which funds bought or sold TYRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	5AM Venture Management, LLC	added	69.25	7,718,030	15,404,500	3.45%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-85.66	-11,543	2,362	-%
May 15, 2024	PDT Partners, LLC	new	-	199,654	199,654	0.02%
May 15, 2024	ACUTA CAPITAL PARTNERS, LLC	sold off	-100	-122,808	-	-%
May 15, 2024	Nextech Invest Ltd.	added	61.04	31,633,800	66,516,100	10.54%
May 15, 2024	Artia Global Partners LP	sold off	-100	-142,004	-	-%
May 15, 2024	Sepio Capital, LP	sold off	-100	-147,156	-	-%
May 15, 2024	ADAR1 Capital Management, LLC	new	-	464,120	464,120	0.10%
May 15, 2024	BARCLAYS PLC	reduced	-48.77	-105,000	161,000	-%
May 15, 2024	Walleye Capital LLC	new	-	276,947	276,947	-%

Are Funds Buying or Selling TYRA?

Are funds buying TYRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TYRA

No. of Funds

Unveiling Tyra Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	3.4%	1,463,115	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	boxer capital, llc	12.3%	6,448,359	SC 13D/A
Feb 06, 2024	ra capital management, l.p.	19.99%	10,475,489	SC 13D/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 16, 2022	boxer capital, llc	15.1%	6,323,359	SC 13D/A
Mar 24, 2022	biotechnology value fund l p	3.2%	1,345,011	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G
Feb 08, 2022	canaan xi l.p.	9.5%	3,936,595	SC 13G

Recent SEC filings of Tyra Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	3	Insider Trading
May 09, 2024	3	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
May 07, 2024	DEFA14A	DEFA14A
May 07, 2024	8-K	Current Report
Apr 22, 2024	EFFECT	EFFECT
Apr 18, 2024	ARS	ARS

Peers (Alternatives to Tyra Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Tyra Biosciences, Inc. News

Latest updates

Tyra Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	79.2%	405	226	238	250	255	266	276	287	299	307	316	-
Current Assets	84.6%	391	212	225	241	247	257	267	277	294	304	314	15.00
Cash Equivalents	340.2%	255	58.00	216	232	242	251	263	275	292	302	313	15.00
Net PPE	-2.1%	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Liabilities	-31.2%	15.00	22.00	16.00	11.00	6.00	8.00	8.00	8.00	8.00	5.00	6.00	2.00
Current Liabilities	-43.2%	9.00	15.00	10.00	5.00	4.00	6.00	5.00	5.00	5.00	4.00	5.00	2.00
Shareholder's Equity	90.9%	390	204	222	239	249	258	268	279	291	302	310	-
Retained Earnings	-11.1%	-183	-164	-142	-120	-107	-95.70	-82.80	-70.29	-55.20	-40.37	-30.44	-14.08
Additional Paid-In Capital	55.4%	573	369	364	359	356	354	351	349	346	342	340	0.00
Shares Outstanding	22.0%	52.00	43.00	43.00	43.00	43.00	42.00	42.00	42.00	42.00	41.00	5.00	2.00
Float	-	-	-	-	267	-	-	-	122	-	-	299	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-62.8%	-22,028	-13,532	-17,145	-9,615	-9,847	-11,980	-12,212	-17,168	-8,925	-9,028	-5,578	-4,461	-4,678	-	-
Share Based Compensation	-1.7%	4,115	4,186	4,377	2,529	2,433	2,909	1,019	2,688	3,972	1,868	507	338	174	-	-
Cashflow From Investing	112.5%	18,073	-144,438	-83.00	-43.00	-41.00	-21.00	-48.00	-251	-239	-105	-240	-240	-60.00	-	-
Cashflow From Financing	61725.6%	200,315	324	467	370	376	3.00	364	27.00	238	-1,508	183,437	-733	130,152	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TYRA Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 17,203	$ 10,408
General and administrative	5,119	3,926
Total operating expenses	22,322	14,334
Loss from operations	(22,322)	(14,334)
Other income:
Interest and other income, net	4,130	2,454
Total other income	4,130	2,454
Net loss	(18,192)	(11,880)
Unrealized loss on marketable securities available-for-sale, net	(387)	0
Comprehensive loss	$ (18,579)	$ (11,880)
Net loss per share, basic	$ (0.35)	$ (0.28)
Net loss per share, diluted	$ (0.35)	$ (0.28)
Weighted average Number of shares outstanding, Basic	52,228,934	42,394,623
Weighted average shares number of shares outstanding, Diluted	52,228,934	42,394,623

TYRA Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 254,366	$ 58,006
Marketable securities	128,096	145,463
Prepaid and other current assets	8,316	8,202
Total current assets	390,778	211,671
Restricted cash	1,000	1,000
Property and equipment, net	1,593	1,628
Right-of-use asset	6,412	6,526
Other long-term assets	4,958	5,032
Total assets	404,741	225,857
Current liabilities:
Accounts payable	2,879	4,662
Lease liabilities, current	370	280
Accrued and other current liabilities	5,467	10,391
Total current liabilities	8,716	15,333
Lease liabilities, noncurrent	6,117	6,216
Other long-term liabilities	29	46
Total liabilities	14,862	21,595
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value; 50,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023.	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 52,521,050 and 43,099,055 shares issued at March 31, 2024 and December 31, 2023, respectively, and 52,474,533 and 43,024,634 shares outstanding at March 31, 2024 and December 31, 2023, respectively.	5	4
Additional paid-in capital	572,902	368,707
Accumulated other comprehensive income (loss)	(6)	381
Accumulated deficit	(183,022)	(164,830)
Total stockholders' equity	389,879	204,262
Total liabilities and stockholders' equity	$ 404,741	$ 225,857

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÃƒâ€¦P, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

CEO	Dr. Todd Harris Ph.D.
WEBSITE	tyra.bio
INDUSTRY	Biotechnology
EMPLOYEES	38

Tyra Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Tyra Biosciences, Inc.? What does TYRA stand for in stocks?

TYRA is the stock ticker symbol of Tyra Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tyra Biosciences, Inc. (TYRA)?

As of Thu May 16 2024, market cap of Tyra Biosciences, Inc. is 1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TYRA stock?

You can check TYRA's fair value in chart for subscribers.

What is the fair value of TYRA stock?

You can check TYRA's fair value in chart for subscribers. The fair value of Tyra Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tyra Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TYRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tyra Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether TYRA is over valued or under valued. Whether Tyra Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Tyra Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TYRA.